As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
An attempt to abrogate the placebo response does not seem to have gone as planned.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.